Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC6 | Q9Y210 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.43 |
| ▸ | GABRP | O00591 | 2/20 | 0.41 |
| ▸ | GABRD | O14764 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30783142 | 1.00 | TRPC6 (0.52) | TRPC6SMN1; SMN2KDM4EGLAHTT | |
| SCHEMBL27676281 | 0.94 | TRPC6 (0.48) | TRPC6SMN1; SMN2KDM4EGLAHTT | |
| SCHEMBL611802 | 0.91 | TRPC6 (0.47) | TRPC6SMN1; SMN2KDM4EGLAHTT | |
| SCHEMBL608705 | 0.87 | QDPR (0.55) | TRPC6TNKSQDPR | |
| SCHEMBL159379 | 0.84 | GABRP (0.43) | TRPC6SMN1; SMN2KDM4EGLAHTT | |
| SCHEMBL28143370 | 0.84 | KDM4E (0.44) | TRPC6SMN1; SMN2KDM4EGLAHTT | |
| SCHEMBL27926722 | 0.83 | TRPC6 (0.51) | TRPC6TNKSEGLN1 | |
| SCHEMBL265000 | 0.82 | SLC18A3 (0.51) | SMN1; SMN2QDPRKCNH2BACE1NAMPT | |
| SCHEMBL10179413 | 0.82 | KDM4E (0.68) | TRPC6SMN1; SMN2KDM4EGLAHTT | |
| SCHEMBL21045776 | 0.80 | TRPC6 (0.54) | TRPC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-27 | — | — | US | disclosed |
| EP-4050012-A1 | PYRIDONE BORONATES FOR THE PREPARATION OF INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2022-08-31 | — | — | EP | disclosed |
| EP-4019508-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2022-06-29 | — | — | EP | disclosed |
| EP-3521288-B1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | HOFFMANN LA ROCHE (CH) | 2021-09-08 | — | — | EP | disclosed |
| US-20210079002-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| US-RE48239-E1 | Heteroaryl pyridone and aza-pyridone compounds | GENETECH, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10696678-B2 | Kinase inhibitor, and preparing method and pharmaceutical use thereof | GAN & LEE PHARMACEUTICALS (CN) | 2020-06-30 | — | — | US | disclosed |
| US-10660888-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2020-05-26 | — | — | US | disclosed |
| US-8716274-B2 | Heteroaryl pyridone and aza-pyridone compounds | GENENTECH, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130178461-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8481540-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2603500-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-06-19 | — | — | EP | disclosed |
| WO-2013067274-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | GENENTECH, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130116235-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| EP-2566869-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | Gilead Connecticut, Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| WO-2012020008-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | disclosed |
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN JOSEPH (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2011140488-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GILEAD CONNECTICUT, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10660888-B2 | Aminoheteroaryl benzamides as kinase inhibitors | ABL1, MAP3K12, MAP3K2 | TRPC6 1202/4885SMN1; SMN2 4410/4885KDM4E 657/4885 |
| US-10696678-B2 | Kinase inhibitor, and preparing method and pharmaceutical use thereof | CDK1, MAP3K1, CSNK1A1 | TRPC6 2977/4885SMN1; SMN2 1869/4885KDM4E 1543/4885 |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | TRPC6 4706/4885SMN1; SMN2 1955/4885KDM4E 325/4885 |
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | TRPC6 3233/4885SMN1; SMN2 4068/4885KDM4E 330/4885 |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | TRPC6 1936/4885SMN1; SMN2 3549/4885KDM4E 1352/4885 |
| US-20130116235-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | BTK, PDXK, TYK2 | TRPC6 2640/4885SMN1; SMN2 3164/4885KDM4E 1658/4885 |
| US-20210079002-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | TRPC6 1936/4885SMN1; SMN2 3549/4885KDM4E 1352/4885 |
| US-20130178461-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | TRPC6 3233/4885SMN1; SMN2 4068/4885KDM4E 330/4885 |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK1, CDK3 | TRPC6 4706/4885SMN1; SMN2 1955/4885KDM4E 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.